Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies

Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft‐versus‐host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

“…The potential role of active CMV infection in promoting aGvHD in allo-HSCT remains a matter of debate aGvHD. [3][4][5][6][7][8][9][10][11][12] Other studies, in addition to the above-mentioned study by Cantoni and colleagues, 4 also pointed to a relationship between the two Similarly, Akakoshi and colleagues, 12 in a very large study, found an independent association between CMV pp65 antigenemia and TA B L E 4 CMV DNAemia as a risk factor for subsequent aGvHD in multivariate models according to aGvHD grades and concomitance of CMV DNAemia at the time of aGvHD occurrence grade II-IV aGvHD (adjusted HR, 1.21). In that study, however, pre-engraftment episodes of CMV DNAemia were not taken into consideration.…”

“…2 Data had been published either supporting or refuting a mechanistic role of CMV infection in the pathogenesis of aGvHD in this setting. [3][4][5][6][7][8][9][10][11][12] These discrepant results may conceivably be explained by between-study variations in several parameters including patient clinical characteristics, the nature of the aGvHD prophylaxis regimen employed, and notably the method employed for CMV monitoring. In this latter respect, incidence of active CMV infection may be underestimated due to use of the pp65 antigenemia assay, which has limited sensitivity compared to molecular methods.…”

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

“…Using a similar protocol, several transplant centers have reported promising results for unmanipulated haploidentical peripheral blood stem cell transplantation (PBSCT) (22,23) or cotransplantation of unrelated cord blood (UCB) (24)(25)(26) or mesenchymal stem cells (MSCs) (27,28). The 1-year cumulative incidence of CMV DNAemia in patients with hematologic malignancies was 23.5-41.7% in the matched sibling donor (MSD)-SCT group versus 62.1-81.0% in the haploSCT group with peripheral blood stem cells (PBSCs) (29,30). The median time to the onset of CMV DNAemia in the haploSCT group was 33 days (range, 10-159 days) with the 1-year cumulative incidence of CMV disease at 7.9% (95% CI, 3.6-14.3%) (29).…”

“…The 1-year cumulative incidence of CMV DNAemia in patients with hematologic malignancies was 23.5-41.7% in the matched sibling donor (MSD)-SCT group versus 62.1-81.0% in the haploSCT group with peripheral blood stem cells (PBSCs) (29,30). The median time to the onset of CMV DNAemia in the haploSCT group was 33 days (range, 10-159 days) with the 1-year cumulative incidence of CMV disease at 7.9% (95% CI, 3.6-14.3%) (29). In addition, a total of 19.4%-92% of these patients experienced CMV reactivation after combination of haploSCT with UCB or MSCs (24)(25)(26)(27)(28).…”

Survey of HCMV in allogenic and autologous stem cell transplantation by real-time PCR in Kermanshah, west of Iran

“…Since HCMV-DNAemia is an independent risk factor for HCMV infection [18], virological surveillance for virus replication is routinely performed in the first 100 days post-transplant using real-time PCR for monitoring of HCMV-DNA in the blood samples.…”